Insmed Incorporated

Insmed Incorporated

INSM·NASDAQ

$103.86

+0.13%
HealthcareBiotechnology

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

At a Glance

Live Snapshot
Market Cap$22.51B
EPS-6.4100
P/E Ratio-16.20
Earnings Date08/06/2026

insm

Common Stock

Last Annual Value

2.14M

3-Year CAGR

16%

5-Year CAGR

16%

10-Year CAGR

13%

Insmed Incorporated

Insmed Incorporated Competitors Analysis of Common Stock

INSM · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
2.14M
13.1%12.5%13.2% 
RMD logo
ResMed Inc.
NYSE:RMD
761.00K
9.0%5.5%3.1%
5.00M
0.0%N/AN/A
HUM logo
Humana Inc.
NYSE:HUM
33.00M
0.0%0.0%0.0%
3.00M
0.0%0.0%-6.7%
2.96B
2.5%1.0%-0.2%
11.38B
1459.5%419.7%0.7%
144.00K
2.2%1.6%10.7%
Insmed Incorporated

Insmed Incorporated Fair Value Envelope

INSM · NASDAQ

Our analysis suggests that INSM has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $103.86, this represents a potential HIDDEN relative to our calculated worth for Insmed Incorporated.

Intrinsic Value
Current Price: $103.86